Breaking News

Show Full Stories


To view all stories in expanded form, please subscribe.
Send Info
Initiation initiated with a Buy at Stifel » 07:51

$2.05 /

-0.12 (-5.53%)

Stifel analyst Justin…

Stifel analyst Justin Keywood initiated coverage of with a Buy rating and C$3.75 price target. Kneat operates an end-to-end SaaS platform that manages the validation or compliance process in pharmaceutical manufacturing and serves eight of the world's top 10 global pharma companies in transitioning mostly paper-based systems to digital, said Keywood, who sees the stock offering "a good combination of defense and offense."

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.